The aging process: where are the drug opportunities?

New data support a role for growth hormone secretagogue receptor agonists a s rejuvenating agents. Two enzymes critical for the formation of beta-amylo id plaques in Alzheimer's disease have been identified. Estrogen receptor b eta continues to emerge as a potential drug target. The orphan nuclear rece ptor Nurr1 appears to be a target for treatment of Parkinson's disease, and propargylamines are emerging as inhibitors of oxidative damage in neurons.